Investee Company Update: Yooma Wellness Inc.

Seed Innovations Limited
09 May 2023
 

09 May 2023 

 

SEED Innovations Limited

 

("SEED" or the "Company")

 

Investee Company Update: Yooma Wellness Inc.

 

SEED Innovations Ltd, the AIM-quoted company investing in fast-growing and industry-leading businesses with a focus on the medical cannabis, health, and wellness space, notes the suspension of trading of its portfolio company, Yooma Wellness Inc.'s ("Yooma"), common shares on the Canadian Securities Exchange and on Aquis.

 

Yooma anticipates that it will complete the Annual Filings on or before 15 July 2023, and that revocation of the Cease Trade Order and the lifting of the share suspension is expected to occur within a few days after the Annual Filings are made. SEED currently carries its investment in Yooma at £43,000 and expects to write this down to £nil on publication of the annual accounts for the year ended 31 March 2023.

 

Ed McDermott, SEED's CEO, commented: "It is disappointing to see Yooma's shares suspended from trading on the CSE and Aquis today. Whilst Yooma expects to make its Annual Filings as described above, this follows the widely reported very poor operational performance in recent months. For SEED, over time, Yooma has become an immaterial holding and was already written down as at our last published NAV to £43,000. I'm pleased to say we have since had a number of NAV increasing announcements with other portfolio assets including Northern Leaf and South West Brands. Looking ahead, Yooma will be carried at £nil for the year ended 31 March 2023."

 

The full announcement is set out without material changes or adjustments.

 

Yooma Wellness Inc.

('Yooma' or the 'Company' or the 'Group')

 

Suspension of Trading

 

Yooma Wellness Inc (CSE: YOOM) (AQSE: YOOM) announces, further to the announcement of 24 April 2023, that its common shares have been suspended from trading today.

 

The Company anticipates that it will complete the Annual Filings on or before 15 July 2023, and that revocation of the Cease Trade Order and the lifting of the share suspension is expected to occur within a few days after the Annual Filings are made.

 

The directors of the company accept responsibility for the contents of this announcement.

 

- Ends -

 

- Ends -

 

  

For further information on the Company please visit:    www.seedinnovations.co     or contact: 

 

 Ed McDermott 

Lance de Jersey 

SEED Innovations Ltd 

E: info@seedinnovations.co  

  

James Biddle 

Roland Cornish 

Beaumont Cornish Limited, 

Nomad 

T: (0)20 7628 3396 

  

Isabella Pierre 

Damon Heath 

Shard Capital Partners LLP 

Broker 

T: (0)20 7186 9927 

Catherine Leftley 

Isabelle Morris 

Max Bennett 

St Brides Partners Ltd, 

Financial PR 

E: info@stbridespartners.co.uk 

  

 

Notes 

 

Seed Innovations Ltd 

 

SEED Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early-stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each. 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings